Loading company
Loading
Latest quarter · Q3 FY2026
Millions- Total revenues
- 0
- Operating income
- (3)
- Net income
- (3)
MiNK Therapeutics, Inc. (INKT) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Operating income | -$12.6 million | -$11.3 million | 10-K 2026-03-31 · proof | |
| Net income | -$12.5 million | -$10.8 million | 10-K 2026-03-31 · proof | |
| Cash from operating activities | -$5.9 million | -$9.6 million | 10-K 2026-03-31 · proof | |
| Total assets | $14.2 million | $5.7 million | +148.9% | 10-K 2026-03-31 · proof |
| Total liabilities | $28.5 million | $25.3 million | +12.5% | 10-K 2026-03-31 · proof |
| Cash and cash equivalents | $13.4 million | $4.6 million | +191.9% | 10-K 2026-03-31 · proof |
- What was MiNK Therapeutics, Inc. (INKT)'s operating income in fiscal 2025?
- MiNK Therapeutics, Inc. (INKT) reported operating income of -$12.6 million for fiscal 2025 (the year ended Dec 31, 2025), against -$11.3 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
- What was MiNK Therapeutics, Inc. (INKT)'s net income in fiscal 2025?
- MiNK Therapeutics, Inc. (INKT) reported net income of -$12.5 million for fiscal 2025 (the year ended Dec 31, 2025), against -$10.8 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
- What was MiNK Therapeutics, Inc. (INKT)'s cash from operating activities in fiscal 2025?
- MiNK Therapeutics, Inc. (INKT) reported cash from operating activities of -$5.9 million for fiscal 2025 (the year ended Dec 31, 2025), against -$9.6 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
- What are MiNK Therapeutics, Inc. (INKT)'s total assets?
- As of Dec 31, 2025, MiNK Therapeutics, Inc. (INKT) reported total assets of $14.2 million, against $5.7 million a year earlier (+148.9%). Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
- What are MiNK Therapeutics, Inc. (INKT)'s total liabilities?
- As of Dec 31, 2025, MiNK Therapeutics, Inc. (INKT) reported total liabilities of $28.5 million, against $25.3 million a year earlier (+12.5%). Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
- What are MiNK Therapeutics, Inc. (INKT)'s cash and cash equivalents?
- As of Dec 31, 2025, MiNK Therapeutics, Inc. (INKT) reported cash and cash equivalents of $13.4 million, against $4.6 million a year earlier (+191.9%). Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:INKT&period_type=annual&limit=5"Information only, not investment advice.